雄激素受体和表达在三阴性乳腺癌患者的肿瘤组织中。
Androgen Receptor and Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer.
机构信息
Analysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
出版信息
Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):147-156. doi: 10.21873/cgp.20249.
BACKGROUND/AIM: Effective targeted therapies for triple-negative breast cancer (TNBC) are limited. In a subset of TNBC, androgen receptor (AR) plays an important role, while the human proviral integration site for Moloney murine leukemia virus-1 (PIM1) overexpression is also implicated. PIM1 kinases phosphorylate AR, thus regulating its transcriptional activity, regardless of the presence or not of androgens. We evaluated the expression of AR and PIM1 and their prognostic significance in TNBC.
MATERIALS AND METHODS
AR and PIM1 transcripts were quantified by quantitative reverse transcription polymerase chain reaction in formalin-fixed paraffin-embedded tumor from 141 patients with TNBC.
RESULTS
AR was expressed in 38.3%, PIM1 in 10.6%, while co-expression of AR and PIM1 was detected in 7/141 cases (5.0%). No prognostic significance of AR or PIM1 was reached for overall or disease-free survival.
CONCLUSION
Co-expression of AR and PIM1 exists in only in a small percentage of patients with TNBC. The implications of this finding in the therapeutic management of patients with TNBC should be investigated in larger patient cohorts.
背景/目的：有效的三阴性乳腺癌（TNBC）靶向治疗方法有限。在 TNBC 的一个亚组中，雄激素受体（AR）起着重要作用，而 Moloney 鼠白血病病毒-1 （M-MLV）人类前病毒整合位点 1（PIM1）的过表达也与此相关。PIM1 激酶磷酸化 AR，从而调节其转录活性，无论是否存在雄激素。我们评估了 AR 和 PIM1 在 TNBC 中的表达及其预后意义。
材料和方法
采用定量逆转录聚合酶链反应（qRT-PCR）方法检测 141 例 TNBC 患者福尔马林固定石蜡包埋肿瘤组织中 AR 和 PIM1 的转录本。
结果
AR 在 38.3%的患者中表达，PIM1 在 10.6%的患者中表达，而 AR 和 PIM1 的共表达在 7/141 例（5.0%）患者中检测到。AR 或 PIM1 的表达与总生存或无病生存均无相关性。
结论
AR 和 PIM1 的共表达仅存在于一小部分 TNBC 患者中。这一发现对 TNBC 患者的治疗管理的影响应在更大的患者队列中进行研究。
Zotero 插件